The FDA finally greenlit Novo Nordisk’s once-weekly insulin for type 2 diabetes, making it the first US-approved longer-acting alternative to daily basal treatment for this

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.

AZ’s IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the

With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments

→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs